The study, Presented at the International AIDS Conference in Melbourne Last Week, Showed that the HPV Vaccine Works Just as Well for HIV-Positive Patients as it Does for HIV-Negative People
Human Papillomavirus, the most common sexually transmitted infection, occurs in a variety of strains that vary in severity. People will typically become infected with HPV after they have become sexually active, and as such the vaccine is recommended to young people before they become sexually active. Those that are HIV positive tend to be contract a greater number HPV strains, and may experience faster negative effects associated with the virus, such as contracting cervical or anal cancer.
The vaccine Gardasil protects against HPV types 6, 11, 16 and 18 and has shown to ve effective in preventing genital lesions that can lead to cancer.
A study by Veronica Rainone and colleagues at the University of Milan was carried out to assess the safety and efficacy of the HPV vaccine in HIV positive patients who have not been infected with HPV.
The study included 46 HIV-positive men and women (aged 13-27) and 47 HIV-negative people as a control. Those who were HIV-positive had managed the disease using anti retro viral drugs for at least ten year prior to the study.
The vaccine requites three doses to be administered; a first dose, a second dose 2 months later, and a third dose 6 months later. Blood samples of the participants were taken one month after each vaccine was administered, and these sample were taken continuously 18 months prior to the final dose.
The study found that vaccine-induced cell-mediated immunity was not significantly different between HIV-positive and HIV-negative patients, suggesting that the vaccine is safe and effective in HIV patients and that it should be recommended to vaccinate HIV-positive individuals against HPV.